{
      "Rank": 10,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated after three months and DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months",
            "DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months"
      ],
      "ArmGroupInterventionName": [
            "Biological: Human umbilical cord-derived MSCs"
      ],
      "ArmGroupLabel": [
            "Human umbilical cord-derived MSCs and DMARDs",
            "DMARDs"
      ],
      "ArmGroupType": [
            "Experimental",
            "No Intervention"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01420432"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) derived from human umbilical cord/placenta at a dose of 1.0E+6 MSC/kg in subject for the therapy of Ankylosing spondylitis (AS)"
      ],
      "BriefTitle": [
            "Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Ankylosing Spondylitis (AS)"
      ],
      "CentralContactEMail": [
            "chengyun.zheng@ki.se"
      ],
      "CentralContactName": [
            "chengyun zheng, Ph. D"
      ],
      "CentralContactPhone": [
            "+86-531-85875635"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 2013"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Ankylosing Spondylitis"
      ],
      "ConditionAncestorId": [
            "D000001850",
            "D000007239",
            "D000001847",
            "D000009140",
            "D000013122",
            "D000001168",
            "D000007592",
            "D000025242",
            "D000000844"
      ],
      "ConditionAncestorTerm": [
            "Bone Diseases, Infectious",
            "Infections",
            "Bone Diseases",
            "Musculoskeletal Diseases",
            "Spinal Diseases",
            "Arthritis",
            "Joint Diseases",
            "Spondylarthropathies",
            "Ankylosis"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC01",
            "BC05",
            "All",
            "BC23",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Infections",
            "Musculoskeletal Diseases",
            "All Conditions",
            "Symptoms and General Pathology",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Spondylitis",
            "Spondylitis",
            "Ankylosing Spondylitis"
      ],
      "ConditionBrowseLeafId": [
            "M15113",
            "M22188",
            "M15114",
            "M9435",
            "M5520",
            "M4278",
            "M4281",
            "M11249",
            "M15071",
            "M3628",
            "M9773",
            "M22189",
            "M3322",
            "T5412"
      ],
      "ConditionBrowseLeafName": [
            "Spondylitis",
            "Spondylarthritis",
            "Spondylitis, Ankylosing",
            "Infections",
            "Communicable Diseases",
            "Bone Diseases",
            "Bone Diseases, Infectious",
            "Musculoskeletal Diseases",
            "Spinal Diseases",
            "Arthritis",
            "Joint Diseases",
            "Spondylarthropathies",
            "Ankylosis",
            "Spondylarthropathy"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000013166",
            "D000025241",
            "D000013167"
      ],
      "ConditionMeshTerm": [
            "Spondylitis",
            "Spondylarthritis",
            "Spondylitis, Ankylosing"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Single"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "Ankylosing spondylitis (AS) is a chronic, progressive inflammatory rheumatic disease involving primarily the sacroiliac joints and the axial skeleton. The main clinical features are back pain and progressive stiffness of the spine. Oligoarthritis of the hips and shoulders, enthesopathy, and anterior uveitis are common, and involvement of the heart and lungs is rare. The current understanding of the pathogenesis of this disorder is limited.It mainly about to hereditary susceptibility (eg hla-b27),infection and autoimmunity.\n\nAlthough traditional drugs, such as Nonsteroidal antiinflammatory drugs (NSAIDs) disease-modifying antirheumatic drugs (DMARDs such as MTX,SASP OR thalidomide) and steroids have been used in the treatment of AS, however, many studies have indicated that the overall response to these drugs is not satisfied. Addition, the severe side effects of these drugs have also been observed. The management of AS patients therefore remains unsatisfactory and targeted therapies are needed. Human MSCs isolated from human umbilical cord/placenta have been shown to have immunoregulatory, immunosuppressive, stimulating hematopoiesis and tissue repairing properties. This study will evaluate the safety and effectiveness of MSC transplantation in the AS patients.\n\nThis study will last 2 to 3 years. Participants will be randomly assigned to receive either MSC transplant +DMARDs therapy (experimental group) or DMARDs therapy (control group). Patients will undergo MSC transplant at the start of the study on Day 0. After 3 months, patients will receive the second MSC transplantation. After six and twelve months from the first transplantation, patients will be evaluated."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatient age 18~60 years old with plan to infuse MSCs.\nDiagnosis of \"Definite AS\" (arthritis of the spine) as defined by the modified New York criteria\nStable doses of sulfasalazine,methotrexate,thalidomide,hydroxychloroquine, low-dose corticosteroids, and NSAIDs are permitted\nPatients must have an ECOG 0~2.\nNo moderate or sever organ dysfunction: Ejection fraction>45%; Creatinine <176 umol/L.\nNo severe infection.\nEach patient must sign written informed consent.\n\nExclusion Criteria:\n\nOther serious concomitant diseases (uncontrolled/severe kidney, liver, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease)\nPsychiatric condition that would limit informed consent.\nHIV, hepatitis B or C, tuberculosis, other infections\nPositive Pregnancy Test or lactation\nPatient has enrolled another clinical trial study within last 4 weeks.\nContraindications to MSC"
      ],
      "EnrollmentCount": [
            "10"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Human umbilical cord-derived MSCs and DMARDs"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "ANeo",
            "All",
            "ARhu",
            "Derm",
            "Repr",
            "Infl",
            "Analg",
            "Gast"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Antineoplastic Agents",
            "All Drugs and Chemicals",
            "Antirheumatic Agents",
            "Dermatologic Agents",
            "Reproductive Control Agents",
            "Anti-Inflammatory Agents",
            "Analgesics",
            "Gastrointestinal Agents"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M15711",
            "M10855",
            "M14432"
      ],
      "InterventionBrowseLeafName": [
            "Thalidomide",
            "Methotrexate",
            "Sulfasalazine"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "1.0E+6 MSC/kg, IV drop and repeat repeated after three months"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Human umbilical cord-derived MSCs"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Ankylosing Spondylitis",
            "Umbilical Cord/placenta-Derived MSC",
            "Transplantation"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Recruiting"
      ],
      "LastUpdatePostDate": [
            "August 19, 2011"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "August 18, 2011"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Shandong University"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Jinan"
      ],
      "LocationContactEMail": [
            "chengyun.zheng@ki.se"
      ],
      "LocationContactName": [
            "chengyun zheng, Ph. D",
            "Ni Zhang"
      ],
      "LocationContactPhone": [
            "+86-531-85875635"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Sub-Investigator"
      ],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "Department of Hematology of the 2nd Hospital of Shandong University"
      ],
      "LocationState": [
            "Shandong"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "250033"
      ],
      "MaximumAge": [
            "60 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat AS"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Shandong University"
      ],
      "OrgStudyId": [
            "Zhangni"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Department of Hematology of The 2nd Hospital of Shandong University"
      ],
      "OverallOfficialName": [
            "chengyun zheng, Ph. D"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2013"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "ASAS measures symptomatic improvement in AS patients.ASAS=4 domains:patient global assessment of disease activity,pain,function,inflammation.ASAS 20=20% improvement(vs.baseline)and an abosolute change\u22651 units on a 0-10 scale(0=no disease activity;10=high disease activity)for \u22653 domains,and no worsening in remaining domain.\n\nPatient global Pain Function (as measured by the Bath Ankylosing Spondylitis Functional Index - BASFI) Inflammation (mean of the Bath Ankylosing Spondylitis Disease Activity Index - BASDAI question 5 and 6)",
            "erythrocyte sedimentation rate (ESR) level will be mainly observed after transplanting 3, 6,12-month.",
            "imageology will be mainly observed after transplanting 3, 6,12-month.",
            "C-reactive protein (CRP) level will be mainly observed after transplanting 3, 6,12-month."
      ],
      "PrimaryOutcomeMeasure": [
            "The Assessment of Spondyloarthritis International Society (ASAS)20 response",
            "erythrocyte sedimentation rate (ESR)",
            "imageology",
            "C-reactive protein (CRP)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "1 year",
            "1 year",
            "1 year",
            "1 year"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [
            "Chengyun Zheng"
      ],
      "ResponsiblePartyOldOrganization": [
            "Department of Hematology of the 2nd Hospital of Shandong University"
      ],
      "ResponsiblePartyType": [],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Percentages of T regulatory cell population in peripheral blood will be tested in every 3 months after transplanting MSCs for one year",
            "Side effects were observed after the treatment"
      ],
      "SecondaryOutcomeMeasure": [
            "Percentage of systemic T regulatory cell population",
            "Side effects"
      ],
      "SecondaryOutcomeTimeFrame": [
            "1 year",
            "1 year"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "January 2011"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "April 2011"
      ],
      "StdAge": [
            "Adult"
      ],
      "StudyFirstPostDate": [
            "August 19, 2011"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "August 11, 2011"
      ],
      "StudyFirstSubmitQCDate": [
            "August 18, 2011"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}